A
Power Law company profile
ATAI Life Sciences
Biotech & Life Sciences · Berlin, Germany · Founded 2018 · IPO 2021 Unicorn
Valuation
$1.25B
Market cap · Apr/2026
Revenue
$4.1M
Latest reported FY
Global footprint
Where ATAI Life Sciences has talent and traffic
Web traffic by country
25K
monthly visits
across markets
across markets
🇺🇸 United States71.2%
🇬🇧 United Kingdom10.4%
🇨🇦 Canada7.2%
🇩🇪 Germany5.6%
🇫🇷 France2%
Patent intelligence
$11M patent portfolio · 65 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$11M
0.88% of market cap · 24.9× smaller than top peer Ascendis Pharma ($275M)
65 active patent families
Where ATAI Life Sciences innovates
Medicinal chemistryPharmaceutical medicinePharmaceutical SubstancesDimethyltryptamineTryptamines
Below peer median on Legal, Market
Quality vs same-sector peers
ATAI Life Sciences on the five Patsnap quality dimensions
ATAI Life Sciences in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where ATAI Life Sciences concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across ATAI Life Sciences and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee ATAI Life Sciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.